Summary
This 2018 Nature Medicine study presents computational and molecular evidence that specific signatures of T cell dysfunction and immune cell exclusion from the tumour microenvironment can predict individual patient responses to cancer immunotherapy. The work suggests that combined assessment of T cell exhaustion markers and immune infiltration patterns may help stratify patients likely to benefit from immunotherapy. The findings support a mechanistic understanding of immunotherapy resistance rooted in T cell state and tumour immune composition.
UK applicability
The predictive biomarker signatures described may have relevance to UK cancer treatment centres and NHS immunotherapy decision-making, potentially informing patient selection and therapy sequencing. Application would require validation in UK clinical cohorts and integration into established diagnostic pathways.
Key measures
T cell exhaustion markers, immune checkpoint expression, tumour-infiltrating lymphocyte profiles, immunotherapy response outcomes
Outcomes reported
The study identified molecular signatures of T cell dysfunction and immune exclusion that predict response and resistance to cancer immunotherapy. The analysis examined tumour microenvironment characteristics associated with immunotherapy efficacy.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.